ESC Issues First Comprehensive Cardiomyopathy Guidelines The European Society of Cardiology has released new guidelines for cardiomyopathies, their first major comprehensive international guidelines to address diagnosis and treatment of the broad causes of heart muscle dysfunction.

AHA/ACC Issue Updated Chronic Coronary Disease Guidelines The latest clinical practice guideline for managing patients with chronic coronary disease (CCD) takes an evidence-based and patient-centered approach to care and includes key updates on revascularization, beta-blocker use, and routine functional and anatomic testing. Developed by the American Heart Association (AHA), the American College of Cardiology (ACC), and other specialty societies, the 2023 guideline both updates and consolidates ACC/AHA guidelines previously published in 2012 and 2014 for the management of patients with stable ischemic heart disease.

Distress-Related Metabolite Levels Predicts Future Cardiovascular Events A metabolite-based distress score derived from measurements of molecular biomarkers in women related to chronic distress can predict future risk for cardiovascular disease. The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed.

Ending Rheumatic Heart Disease is achievable if we put our heads and minds to it Preventable, yet persistent, Rheumatic Heart Disease (RHD) is the most commonly acquired heart disease in people under 25 years of age. The World Heart Federation (WHF) is committed to the fight to ensure cardiovascular health for everyone. Through WHF’s network of Members and the power of personal testimonials, we are spreading awareness that RHD can be prevented, diagnosed, and treated. This editorial was authored by WHF Director of Policy and Advocacy Jeremiah Mwangi and was first published in FORESIGHT Global Health on 19 August 2021.

Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.

Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.

The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine Dear Colleagues! We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).

Analysis of the activities of the "Cardioprogress" foundation: results of 2021 Dear colleagues! In 2021, a number of significant events took place in cardiology. Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.

Aspirin is linked with increased risk of heart failure Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition. That’s the finding of a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC).